DeutschNewstral
Article
jdsupra.com on 2018-10-19 20:08
AbbVie and Fresenius Kabi Settle Adalimumab Biosimilar Patent Disputes
Related news
- AbbVie and Pfizer Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- AbbVie and Sandoz Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- AbbVie Grants Momenta Global Patent Licenses for Biosimilar of HUMIRA (Adalimumab)jdsupra.com
- China NMPA Approves Adalimumab Biosimilarjdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- European Biosimilar Approval Updates: Adalimumab, Pegfilgrastimjdsupra.com
- AbbVie Licenses Humira® (Adalimumab) Patents to Mylanjdsupra.com
- FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADAjdsupra.com
- Sandoz Launches Adalimumab Biosimilar in Spainjdsupra.com
- Hospira, Inc. v. Fresenius Kabi USA, LLCjdsupra.com
- U.S. Biosimilar Regulatory and Launch Updates: Adalimumab, Filgrastimjdsupra.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilarsjdsupra.com
- Updates On Discovery Rulings in AbbVie v. BI Adalimumab Litigationjdsupra.com
- AbbVie Files Claim Construction Brief in BI Adalimumab Litigationjdsupra.com
- Paper reports on administration of adalimumab biosimilar using an autoinjectorjdsupra.com
- Biosimilar Pipeline Developments: Rituximab, Adalimumab, Eculizumab, Infliximab, Pegfilgrastimjdsupra.com
- Fresenius Kabi Announces FDA Approval of Adalimumab Biosimilarjdsupra.com
- Case Spotlight: Akorn, Inc. v. Fresenius Kabi AGjdsupra.com
- Hospira, Inc. v. Fresenius Kabi USA, LLC (Fed. Cir. 2020)jdsupra.com